710327-19-8

Basic information

• Product Name: ethyl (S)-2-(4-isopropylphenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate
• Synonyms: ethyl (S)-2-(4-isopropylphenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate
• CAS NO: 710327-19-8
• Molecular Weight: 552.67
• Mol File: 710327-19-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: ethyl (S)-2-(4-isopropylphenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl (S)-2-(4-isopropylphenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate(710327-19-8)
• EPA Substance Registry System: ethyl (S)-2-(4-isopropylphenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate(710327-19-8)

Safety Data

• Hazardous Substances Data: 710327-19-8(Hazardous Substances Data)

Upstream product

• 710327-18-7 ethyl (S)-3-[4-(2-tert-butoxycarbonylaminoethoxy)phenyl]-2-(4-isopropylphenoxy)propionate 
• 710327-16-5 ethyl (S)-3-(4-benzyloxyphenyl)-2-(4-isopropylphenoxy)propionate 
• 710327-15-4 (S)-3-(4-benzyloxyphenyl)-2-(4-isopropylphenoxy)propionic acid 
• 710326-97-9 ethyl 3-(4-benzyloxyphenyl)-2-(4-isopropylphenoxy)propionate 
• 710327-17-6 ethyl (S)-3-(4-hydroxyphenyl)-2-(4-isopropylphenoxy)propionate 
• 141109-83-3 ethyl 3-(4-benzyloxyphenyl)lactate 
• 4385-62-0 4-(pyridin-2-yl)benzoic acid 
• 99-89-8 4-Isopropylphenol 

Relevant articles and documents

Synthesis and biological activity of novel α-substituted β-phenylpropionic acids having pyridin-2-ylphenyl moiety as antihyperglycemic agents

We previously reported the identification of novel oximes having 5-benzyl-2,4-thiazolidinedione with antihyperglycemic activity. We now report the synthesis and biological activity of a novel series of oximes and amides having α-substituted-β-phenylpropionic acids. In this series, we obtained potent PPARα/γ dual agonist (S)-9d, with which activation of PPARα and PPARγ was considerably more potent than that of the reference compounds GW9578 22 and rosiglitazone 3, respectively. This means (S)-9d is of the strongest class of PPARα/γ dual agonists. In the course of this study, we also obtained 8h, which indicated potent plasma glucose lowering effect in spite of weak PPARα/γ agonistic activity.